

1 **Interim Quantitative Method for Evaluating the Efficacy of Antimicrobial Test Substances**
2 **on Porous Surfaces against Viruses**

3 (12/12/2022)
4

5 **Scope**

6 The Environmental Protection Agency (EPA) Office of Pesticide Programs (OPP) recommends
7 that applicants utilize this interim method to support the registration of disinfectant products with
8 claims for efficacy against viruses when used on soft-porous surfaces.

9 This method is quantitative and provides log reduction (virus inactivation) as the quantitative
10 measure of efficacy for disinfectants against viruses on soft-porous surfaces.

11 **Method Overview**

12 In brief, the method uses 1 cm diameter discs (carriers) of a set of materials to represent soft-
13 porous surfaces. Each disc receives 10 μL of microbial inoculum (with a three-part organic and
14 inorganic soil load) deposited in the center of each carrier. The inoculum is allowed to dry and is
15 then exposed to 50 μL of the antimicrobial treatment; control carriers receive an equivalent
16 volume of an innocuous fluid (e.g., growth media). The exposure time is allowed to elapse; a
17 liquid neutralizer is then added to the vial to halt the antimicrobial action. Each vial with the
18 carrier is vortexed, serially diluted, and plated onto cells to recover viable virus. The presence of
19 viable virus particles is determined as applicable to the test system (e.g., cytopathic effect (CPE),
20 direct fluorescent antibody (DFA) stain, hemagglutination, etc.). Based on the difference
21 between the mean \log_{10} density values of the untreated control and treated carriers, a \log_{10}
22 reduction (LR) in viable virus is calculated. The LR value is used as the measure of product
23 effectiveness.

24 Appropriate biosafety procedures should always be used when working with laboratory test
25 systems which include human pathogenic microorganisms. Laboratory safety is discussed in the
26 current edition of “Biosafety in Microbiological and Biomedical Laboratories (BMBL)” 6th
27 edition, from the subject matter experts within the U.S. Department of Health and Human
28 Services (HHS), including experts from the Centers for Disease Control and Prevention (CDC)
29 and National Institutes of Health (NIH).

30

TABLE OF CONTENTS

31

1) Special Apparatus and Materials.....	3
2) Carriers.....	5
3) Carrier Inoculation	6
4) Performance Assessment – Efficacy.....	8
5) Data Requirements.....	9
Attachment 1: Neutralization Assay and Flowchart.....	11
Attachment 2: Cytotoxicity Determination.....	13

32

Interim

33 **1) Special Apparatus and Materials**

34 a. Test Virus, use appropriate virus to be claimed on the label.

35 b. Cell Line, appropriate for the virus tested.

36 c. Media and reagents:

37 i. *Complete Growth Media (CGM)*. Consisting of Minimum Essential Media and
38 FBS or other medium specified for the virus being tested. Used for cell line
39 propagation, viral propagation, and serial dilution. Antibiotics and/or antifungals
40 may be added to reduce potential contamination.

41 1. *Minimum Essential Media (MEM)*. Liquid or powder form (e.g. Eagle's or
42 Dulbecco's). Used to prepare complete growth media. Prepare per
43 manufacturer's guidelines.

44 2. *Heat Inactivated Fetal Bovine Serum (FBS)*. Compatible for use with cell
45 lines. Often used to prepare complete growth media.

46 ii. *Neutralizer*. Used to inactivate and/or dilute the antimicrobial treatment to end the
47 contact time.

48 1. Note: The recommended neutralizer for the test system is the same
49 medium used to grow the virus (e.g., CGM). If the neutralization
50 confirmation assay demonstrates that CGM is ineffective, other
51 neutralizers may be used.

52 iii. *Dulbecco's Phosphate buffered saline (DPBS)*. Or other equivalent buffer (e.g.
53 PBS, Earle's Balanced Salt Solution). Prepare per manufacturer's guidelines.

54 iv. *Antibiotic/antifungal*. 100x Amphotericin B/Penicillin/Streptomycin solution or
55 other equivalent antibiotic/antimycotic solution. May be used to prevent
56 contamination of cell culture.

57 v. *Soil load, 3-part*. Use as the soiling agent. Add to the test suspension in the
58 following manner:

59 1. BSA: Add 0.5 g bovine serum albumin (BSA, radio immunoassay (RIA)
60 grade or equivalent, CAS# 9048-46-8) to 10 mL of PBS, mix and pass
61 through a 0.2 µm pore diameter (polyethersulfone) membrane filter,
62 aliquot (e.g., a minimum of 50 µL), and store at -20±2°C.

63 2. Yeast Extract: Add 0.5 g yeast extract to 10 mL of PBS, mix, and pass
64 through a 0.2 µm pore diameter (polyethersulfone) membrane filter,
65 aliquot (e.g., a minimum of 70 µL), and store at -20±2°C.

66 3. Mucin: Add 0.04 g mucin (from bovine submaxillary gland, CAS #
67 84195-52-8) to 10 mL of PBS, stir or vortex-mix until thoroughly
68 dissolved, and pass through a 0.2 µm pore diameter (polyethersulfone)
69 membrane filter, aliquot, and store at -20±2°C.


- 70 4. The three stock solutions of the soil load are single use only. Do not
71 refreeze; store up to one year at $20\pm 2^{\circ}\text{C}$.
- 72 vi. *Antimicrobial Test Substance*. Ready-to-use, activated, or concentrated
73 antimicrobial. If the antimicrobial test substance is prepared by diluting a
74 concentrate, adequately mix antimicrobial test substance with the appropriate
75 diluent (e.g., hard water), then use prepared test substance within 3 hours of
76 preparation or as otherwise instructed by the manufacturer. Measuring error
77 increases as delivery volume decreases. To minimize variability due to measuring
78 error, a minimum of 1.0 mL or 1.0 g of concentrated antimicrobial test substance
79 should be used when preparing use-dilutions for testing. Use v/v dilutions for
80 liquid antimicrobial test substances and w/v dilutions for solid antimicrobial test
81 substances. The use of a positive displacement pipette is recommended for
82 viscous liquids.
- 83 vii. *Water*. De-ionized (DI), distilled water or water with equivalent quality for
84 making reagent solutions and culture media.
- 85 d. Apparatus
- 86 i. *Carriers*: Discs (1 cm in diameter) cut from porous material. Carriers are single
87 use only. See section 2 for carrier specifications.
- 88 ii. *Hole punch*: If necessary, for use in the preparation of 1 cm discs from material.
89 Model number: SKU# HP-MEI448R or equivalent.
- 90 iii. *Calibrated 10 μL positive displacement pipette* with corresponding 10 μL tips, for
91 carrier inoculation.
- 92 iv. *Filter paper*. Whatman No. 2, to line glass Petri plates.
- 93 v. *Calibrated micropipettes* (e.g., 200 μL , 1 mL) with appropriate corresponding
94 tips, for deposition of test substance on carriers and preparing dilutions.
- 95 vi. *Forceps*, straight or curved, non-magnetic, disposable with smooth flat tips to
96 pick up the carriers for placement in vials.
- 97 vii. *Vials with lids* (plastic or comparable). Sterile, flat-bottomed, wide-mouthed (at
98 least 25 mm diameter), approximately 20 mL capacity, for holding inoculated
99 carriers to be exposed to the test chemical and for accommodating neutralizer.
- 100 1. Transparent vials are more desirable to facilitate application of 50 μL test
101 substance or control substance to inoculated carrier.
- 102 viii. *Certified timer*. Readable in minutes and seconds, for tracking of timed events and
103 intervals.
- 104 ix. *Desiccation unit* (with gauge to measure vacuum) with fresh desiccant (e.g.,
105 anhydrous CaCl_2). For drying inoculated carriers.

- 106 x. *Vacuum source*. In-house line or suitable vacuum pump capable of achieving
- 107 0.068 to 0.085 MPa, for drying inoculated carriers in desiccation unit and to
- 108 perform membrane filtration.
- 109 xi. *Titration kit* (e.g. Hach digital titrator). For measuring water hardness.
- 110 xii. *Vortex-style mixer*. For vortex-mixing of various solutions.
- 111 xiii. *15 mL conical centrifuge tubes*. For serial dilutions.
- 112 xiv. *Water bath*. To maintain cell culture media at 37±1°C.
- 113 xv. *Tissue/cell culture flasks (tissue culture treated)*. Flasks for cell propagation.
- 114 xvi. *Cell plates*. 24-well plates used to assay virus from control and treated carriers.
- 115 xvii. *Centrifuge (with swinging bucket rotor)*. For preparing frozen virus stock.
- 116 xviii. *Ultracentrifuge* (capable of spinning 100,000 x g). For concentrating virus stock
- 117 if needed.
- 118 xix. *Inverted microscope*. For viewing cells.
- 119 xx. *Incubator with 5% CO₂*. For incubation of virus/cell line test system

121 2) Carriers

122 a. Carrier Materials (see Figure 1)

- 123 i. Privacy Curtain Fabric (PCF-03): 54% Polyester, 46% Fire Resistant (FR)
- 124 Polyester. CF Stinson, LLC. Mambo MAM34 Nights.
- 125 ii. Non-PVC Fabric (NVF-01): Polyurethane Face made with Polycarbonate and
- 126 Polyether Resins, Polyester Backing. CF Stinson, LLC. Kid BlueSky KID17.
- 127 iii. Vinyl Seating Fabric (VF-01): Vinyl Face, Polyester Backing. CF Stinson, LLC.
- 128 Hopsack - HOP24 Fjord.



129 **Figure 1:** Examples of carrier materials cut into 1 cm discs; materials 2.a.i, 2.a.ii,
 130 and 2.a.iii (from left to right)

131 b. Carrier Preparation

- 132 i. Punch 1 cm round carriers or use comparable cutting procedure from fabric.

- 133 ii. Visually screen carriers to ensure consistent surface characteristics; trim any
134 jagged edges or loose fabric.
- 135 iii. No pre-cleaning of carriers is necessary. To sterilize carriers, sterilize using a
136 gravity cycle, 121°C for 20 minutes; ensure carriers are dry following
137 sterilization. Test sterility of carriers prior to testing.
- 138 1. Carriers may not be entirely flat after autoclaving; however, minor
139 distortion of carriers is acceptable for testing.
- 140 2. Prior to use in testing, document the condition of the screened and sterile
141 carriers (e.g., digital photographs).
- 142 c. Carrier Cytotoxicity Check
- 143 i. Each carrier type should be tested for any cytotoxic effects on the cell line. Place
144 a carrier into 10 mL of the proposed neutralizer and let soak for ten minutes. Add
145 1 mL per well of this solution to a 24 well plate with a confluent monolayer of
146 cells. Incubate plate at the required conditions and time; observe daily for
147 cytotoxicity. No cytotoxicity should be observed.

148

149 **3) Carrier Inoculation**

- 150 a. Propagate the virus on the appropriate cell line.
- 151 Note: Concentration of the virus stock (~100,000 x g for 4 hours at 4° C) may be necessary to
152 achieve adequate control counts.
- 153 b. Defrost a cryovial rapidly to avoid loss in the viability of the preserved virus (e.g., place
154 in a 37°C water bath and use within 15 min after thawing).
- 155 c. Dilute the virus stock with CGM to achieve control counts in the range of 4.0 to 5.5 logs
156 virus particles/carrier.
- 157 d. Use the diluted virus to prepare the final test suspension with the addition of the soil load.
- 158 e. To obtain 500 µL of the final test suspension with the 3-part soil load, vortex-mix each
159 component and combine in the following order using a calibrated micropipette (smaller
160 volumes may be used proportionally):
- 161 i. 25 µL BSA stock
- 162 ii. 35 µL yeast extract stock
- 163 iii. 100 µL mucin stock
- 164 iv. Vortex soil suspension for 10 s prior to adding microbial test suspension.
- 165 i. 340 µL virus test suspension
- 166 f. It is advisable to briefly rescreen each sterilized carrier for abnormalities prior to
167 inoculation. Place carriers screened side up inside an empty, sterile plastic Petri dish (no
168 more than 20 carriers/dish).

- 169 i. Privacy curtain carriers have no backing material and may be inoculated on either
170 side
- 171 ii. Non-PVC and vinyl carriers are layered materials comprised of a smooth, colored
172 top surface and a white fabric bottom; only the top surface will be inoculated.
- 173 g. Vortex-mix the final test suspension for 10 s following the addition of the virus test
174 suspension and immediately prior to use. Inoculate carriers within 30 min of preparation.
- 175 i. If a smaller test suspension is prepared, pipetting to mix may be used.
- 176 ii. Inoculate the number of carriers required for the evaluation of the test substance
177 (3 controls and 5 treated) along with a few extra carriers.
- 178 h. Using a calibrated positive displacement pipette with a 10 μ L tip, withdraw 10 μ L of the
179 final test suspension and deposit it at the center of each carrier (clean, screened and
180 sterile); avoid contact of pipette tip with carrier and do not spread the final test
181 suspension with the pipette tip.
- 182 i. For consistency, vortex-mix the final test suspension frequently during
183 inoculation of the carrier set.
- 184 ii. The same pipette tip may be used to inoculate all carriers (unless the tip is
185 compromised).
- 186 iii. Discard any inoculated carrier where the final test suspension has run over the
187 edge.
- 188 i. Transfer the Petri dish(es) with the inoculated carriers into a desiccation unit (with
189 desiccant) and completely remove the lid of the Petri dish. Close the desiccation unit door
190 (or lid) and seal the unit. Apply vacuum to evacuate the desiccation unit.
- 191 j. Maintain and monitor the vacuum level using a gauge. Achieve and maintain consistent
192 level of vacuum (at 20-25 in of mercury, 508-635 torr, 677-847 mbar, or 68000-85000
193 Pascal) throughout the carrier drying process.
- 194 k. Hold the inoculated carriers in the evacuated desiccation unit at $21\pm 3^{\circ}\text{C}$ for 45 to 60 min.
195 Inspect inoculated carriers to verify that they are not visibly wet and remove from
196 desiccation unit. Do not use carriers that are visibly wet for testing.
- 197 i. Record the time for all timed events.
- 198 ii. Depressurize the desiccator slowly to avoid the potential for carriers to move or
199 flip.
- 200 l. Use dried inoculated carriers for testing within 30 min following removal from
201 desiccation unit; hold carriers in closed Petri dish at room temperature ($21\pm 3^{\circ}\text{C}$) until
202 use.

203

204 4) **Performance Assessment – Efficacy**

- 205 a. Evaluate 3 untreated control carriers and 5 treated carriers per test substance.

- 206 i. One set of untreated control carriers may be used for evaluating multiple test
207 substances against the same virus on the same test day (assuming the carrier
208 material, neutralizer, and soil load are the same).
- 209 b. Using sterile forceps, transfer each dried carrier with the inoculated side up to a flat-
210 bottom vial and cap the vial. Repeat until all carriers are transferred.
- 211 c. Prepare the antimicrobial test substance. Use antimicrobial test substance within 3 hours
212 of preparation or as specified by the manufacturer.
- 213 d. In a timed fashion with appropriate intervals, sequentially deposit 50 μL of the test
214 substance (equilibrated to $21\pm 3^\circ\text{C}$) with a calibrated micropipette over the dried
215 inoculum on each test carrier, ensuring complete coverage.
- 216 i. Note: Gently apply the antimicrobial test substance at a perpendicular angle to the
217 inoculated carrier; do not forcefully deposit the disinfectant.
- 218 e. Use a new tip for each carrier; do not touch the carrier surface with a pipette tip during
219 the application of the test substance or the control substance; replace with new carrier(s)
220 and vial(s) if this occurs. Do not cap the vials.
- 221 i. For non-foaming aerosols and pump/trigger spray products, obtain the test
222 substance by dispensing the product into a sterile vessel for collection. Cap the
223 vessel and use dispensed product within 30 min.
- 224 ii. For foaming spray formulations, allow the foam to break down for at least 5-10
225 minutes for the generation of a 1-2 mL liquid sample. Cap the vessel and use
226 dispensed product within 30 min.
- 227 f. Do not process carriers where the test substance runs off the carrier or does not
228 completely cover the inoculum spot; replace with new carrier(s) and vial(s) if this occurs.
- 229 g. Conduct the test at room temperature ($21\pm 3^\circ\text{C}$) for the selected contact time. Use a
230 certified timer to ensure that each carrier receives the required contact time.
- 231 h. Process control carriers last. Each control carrier receives 50 μL CGM equilibrated to
232 $21\pm 3^\circ\text{C}$, instead of the test substance. Hold the control carriers for the same contact time
233 as used for the test substance.
- 234 i. Within ± 5 s of the end of the contact period, add neutralizer equilibrated to $21\pm 3^\circ\text{C}$ to
235 each vial in the specified order according to the predetermined schedule. Briefly vortex-
236 mix (2-3 s) each vial following the addition of the neutralizer.
- 237 i. The vial containing the neutralized solution with carrier is considered to be the
238 10^0 dilution.
- 239 ii. Use the same neutralizer for the control carriers as that for the treated carriers.
- 240 iii. If deemed necessary, the final volume of neutralizer may be increased to 20 mL
241 (for all carriers).

- 242 j. Following the neutralization of the entire set of carriers, vortex-mix each vial for 30 ± 5 s
243 at high speed to recover and disaggregate the inoculum. Do not remove the carrier from
244 the vial.
- 245 k. Initiate dilutions within 30 min after neutralization and vortex-mixing. Initiate
246 inoculation of cell line within 30 min of preparing the dilutions.
- 247 l. Titrate the samples for virus infectivity using the appropriate cell line using 8 wells per
248 dilution.
- 249 m. Plate a minimum of 80% of the volume (8mL for 10 mL neutralizer, 16 mL for 20 mL) of
250 the 10^0 vial and of each dilution tube.
- 251 i. Remove the growth medium from each well of the plate with a confluent
252 monolayer of cells and replace with the maximum volume of the dilution tube (i.e.
253 add 1 mL per well for a 24 well plate) working from most dilute to least dilute.
- 254 n. The elution steps for control carriers are the same as for the test carriers; use 10-fold
255 dilutions to achieve 4.0 – 5.5 logs virus particles/carrier.
- 256 o. If cytotoxicity was observed in pre-neutralization testing and/or on the cytotoxicity
257 control, CGM may be removed from all wells in the affected dilutions at the appropriate
258 time (one hour minimum) and wash them with pre-warmed PBS, then replace the PBS
259 with fresh CGM.
- 260 p. Incubate test and control plates as appropriate for the test system.

261 5) Data Requirements

- 262 a. Record all observations (presence/absence of viable virus particles) and use in
263 calculations to estimate the log reduction based on the TCID₅₀ or MPN (most probably
264 number) technique.
- 265 b. Use values with at least three significant figures when performing calculations (e.g., log
266 density, mean log density). Report the final mean log reduction value with two significant
267 figures (e.g., round up to the nearest tenth).
- 268 c. Calculate the TCID₅₀/carrier or MPN/carrier. Calculate the log density of each carrier by
269 taking the log₁₀ of the density (per carrier).
- 270 d. Calculate the mean log₁₀ density across treated carriers.
- 271 e. Calculate the mean log₁₀ density across control carriers.
- 272 Calculate the log₁₀ reduction (LR) for treated carriers: $\log_{10} \text{reduction} = \text{mean log}_{10}$
273 $\text{control} - \text{mean log}_{10} \text{treated}$.

274

275 **Attachment 1**

276

Neutralization Assay

277 The purpose of this section is to assess the effectiveness of the neutralization processes
278 associated with this method. Perform the neutralization assay prior to testing to demonstrate
279 the neutralizer's ability to inactivate the chemical and determine if there is interference from
280 the carrier itself.

281 Select a neutralizing medium that is not inhibitory to the virus and is not cytotoxic to the
282 cells. The acceptance criteria for acceptable neutralization is 0.5 log difference between the
283 neutralization effectiveness, neutralization toxicity control, titer control, and carrier control.
284 Interaction between the neutralizer and product and its effect on the cell line must be
285 determined prior to testing.

286 1) Prepare *Test Suspension A*: Dilute the virus stock suspension in CGM to achieve an
287 average recovered concentration of approximately 2-3 logs (i.e., 100-1000 virus particles)
288 per vessel for the Titer Control sample. To achieve this, dilute the virus stock suspension
289 through 10^{-4} (or as necessary).

290 2) Prepare *Test Suspension B*: Prepare the soil load: vortex each component and combine
291 25 μL bovine serum albumin (BSA), 35 μL yeast extract, 100 μL of mucin, and 340 μL
292 of *Test Suspension A* (0.5 mL total volume) and mix well. Use *Test Suspension B*
293 within 30 minutes of preparation.

294 3) Neutralization Treatments (**Figure 2**)

295 a. **Treatment 1: Neutralizer Effectiveness.** Add 50 μL of the test substance to each
296 of three test tubes. At timed intervals, add 10 mL (up to 20 mL) neutralizer to
297 each vessel and briefly swirl (by hand). After 10 ± 2 s, gently add 10 μL of *Test*
298 *Suspension B* using a micropipette to each vessel. Use a new tip for each tube.
299 Vortex each tube for 3-5 s. Proceed with step 3.

300 b. **Treatment 2: Neutralizer Toxicity Control.** Add 10 mL neutralizer to each of three
301 reaction vessels. At timed intervals, add 10 μL of *Test Suspension B* using a
302 micropipette to each vessel. Use a new tip for each tube. Vortex each tube for 3-5
303 s. Proceed with step 3.

304 c. **Treatment 3: Titer Control.** Add 10 mL CGM to each of three reaction vessels.
305 At timed intervals, add 10 μL of *Test Suspension B* using a micropipette to each
306 vessel. Use a new tip for each tube. Vortex each tube for 3-5 s. Proceed with step
307 3.

308 d. **Treatment 4: Carrier Interference Control.** Add 10 mL CGM and one sterile
309 carrier to each of three reaction vessels. At timed intervals, add 10 μL of *Test*
310 *Suspension B* using a micropipette to each vessel. Use a new tip for each tube.
311 Vortex each tube for 3-5 s. Proceed with step 3.

312 e. Note: Steps should be conducted at timed intervals (e.g., 30 s) to ensure
313 consistent time of contact for each carrier.

314 4) Hold the neutralization treatments for 10 ± 1 minutes at room temperature ($21 \pm 3^\circ\text{C}$).

- 315 5) At the conclusion of the holding period, vortex each tube for 3-5 s. Serially dilute the
316 sample as needed (e.g., remove 1 mL of sample and dilute in 9 mL of CGM).
- 317 a. Initiate dilution and plating as soon as possible (e.g., within 5 minutes). Two
318 analysts are recommended to perform vortexing and dilution steps to reduce
319 holding time after vortexing.
- 320 b. Titrate the samples for virus infectivity using the appropriate cell – plate a
321 minimum of 80% of the 10^0 vial and all dilutions.
- 322 i. For each well plated, add the maximum volume of the well (i.e. add 1 mL
323 per well for a 24 well plate).
- 324 ii. Note: If any 10^0 (vessel) dilution is used that does not contain CGM (e.g.
325 Treatment 2 with proposed neutralizer), allow it to adsorb on the cells for
326 1 hr, then remove and replace with fresh CGM.
- 327 c. If cytotoxicity was observed in pre-neutralization testing CGM may be removed
328 from all wells in the affected dilutions at the appropriate time (one hour
329 minimum) and wash them with pre-warmed PBS, then replace the PBS with fresh
330 CGM. Also wash with pre-warmed PBS and replace the CGM in the same
331 dilutions for the control carriers.
- 332 d. Incubate test and control plates as appropriate for the test system.
- 333 e. For the neutralizer to be considered effective:
- 334 i. Ensure that the recovered virus in the **Titer Control** using *Test*
335 *Suspension B* is between approximately 2-3 logs per vessel.
- 336 ii. The recovered virus in the **Neutralizer Effectiveness** treatment is within
337 0.5 logs of the **Titer Control**; this verifies effective neutralization. A log
338 reduction greater than 0.5 logs indicates that the neutralizer was not
339 effective. Note: a value higher than the **Titer Control** is also deemed
340 valid.
- 341 iii. The recovered virus in the **Neutralizer Toxicity Control** is within 0.5
342 logs of the **Titer Control**. A log reduction greater than 0.5 logs
343 indicates that the neutralizer is harmful to the test system. Note: a
344 value higher than the **Titer Control** is also deemed valid.
- 345 iv. The recovered virus in the **Carrier Interference Control** is within 0.5
346 logs of the **Titer Control**. A log reduction greater than 0.5 logs
347 indicates that the carrier is harmful to the test system. Note: a value
348 higher than the **Titer Control** is also deemed valid.
- 349 f. All criteria in step e must be met. If the criteria are not met, another neutralizer or
350 mixture of neutralizers must be identified and verified.
- 351

352 **Attachment 2**

353 **Cytotoxicity Determination**

354 Prior to performing the neutralization assay, ensure the proposed neutralizer, neutralizer and test
355 chemical, and the soil used do not impact the quality of the cell line by performing the following.

356 1) Neutralizer Effect on Cell Line (for neutralizers other than CGM with 2% CGM).

357 a) Add 0.5 mL of the proposed neutralizer to 4.5 mL CGM with 2% (v/v) FBS, equilibrated
358 to $37\pm 1^\circ\text{C}$ (this is the 10^{-1} dilution). It is suggested to do further dilutions out to 10^{-2} or
359 10^{-3} depending on the expected cytotoxicity of the neutralizer.

360 b) Remove the CGM from the wells of a 24 well plate with an 80-95% confluent monolayer
361 of cells and add 1 mL per well of the neutralizer plus CGM solution. Plate at least 4 wells
362 per dilution. Have at least one well as a negative control (e.g., CGM with 2% FBS alone).

363 c) Incubate plate as appropriate and observe closely for cytotoxicity.

364 d) If cytotoxicity is observed after one hour, remove the media in a single well of the
365 affected dilution, rinse once with pre-warmed DPBS (the DPBS wash step may be
366 omitted if the cytotoxicity is mild), and replace media.

367 e) If cell death occurs in under one hour, the neutralizer cannot be tested.

368 f) The effect of the media change in the single well can be compared to the other wells in
369 the dilution and the negative control. If cytotoxicity cannot be overcome with washing
370 and replacing of media, column filtration (e.g., Sephadex) may be used in future testing.

371 2) Neutralizer Plus Test Chemical Effect on Cell Line.

372 a) Add 50 μL of test chemical and 20 mL of neutralizer, equilibrated to $21\pm 3^\circ\text{C}$, and vortex
373 2-3 seconds. Let this solution sit at room temperature for 10 minutes.

374 b) Add 1.0 mL of this solution to 9 mL CGM with 2% (v/v) FBS, equilibrated to $37\pm 1^\circ\text{C}$
375 (this is the 10^{-1} dilution). It is suggested to do further dilutions out to 10^{-2} depending on
376 the expected cytotoxicity.

377 c) Remove the CGM from the wells of a 24 well plate with an 80-95% confluent monolayer
378 of cells and add 1 mL per well of the neutralizer plus test chemical solution and dilutions.
379 Plate at least 8 wells for the 100 dilution, 6 wells for the 10^{-1} dilution, and 4 wells is for
380 the 10^{-2} dilution. Extra wells will be needed to observe the effect of no media changes or
381 for further media changes as needed.

382 d) For highly toxic test chemicals, washing the cells with pre-warmed DPBS before the
383 addition of CGM with 2% FBS will help remove cytotoxicity.

384 e) Have at least one well on each plate as a negative control (e.g., CGM with 2% (v/v) FBS
385 alone).

386 f) At a minimum, change the media in the wells as outlined below. Change the media at the
387 lower time interval if they look more toxic. Other media changes can be made at other
388 times if necessary.


- 389 i) For the 10⁰ dilution: On the day of the test, change 2 wells 1-2 hours (1-hour
390 minimum) after the neutralizer/test chemical mixture was added to the cells. Change
391 2 more wells 3-5 hours after the neutralizer/test chemical mixture was added to the
392 cells. The next day, change 1 each of the 1-2 hour and 3-5 hour wells, as well as
393 another, previously unchanged well.
- 394 ii) For the 10⁻¹ dilution: On the day of the test, change 2 wells 3-5 hours after the
395 neutralizer/test chemical mixture was added to the cells. The next day, change 1 of
396 these wells as well as another, previously unchanged well.
- 397 iii) For the 10⁻² dilution: On the day after the test, change 1 well.
- 398 g) Incubate the plate as appropriate and observe the cells for cytotoxicity. The test cells
399 should be compared to the negative control cells to determine toxicity.
- 400 h) Score the cells as toxic or non-toxic in each in each test conditions.
- 401 i) Identify the test condition that removed the cytotoxicity and use that condition for further
402 neutralization and efficacy testing. Use the test condition that allows the media to stay on
403 the cells for as long as possible.
- 404 i) **Example:** In the 10⁰ dilution, if the unchanged wells are toxic, but both the 1 hour
405 and 4 hour media changes are non-toxic, change the media in the 100 dilutions after 4
406 hours in all future testing.
- 407 j) If cell death occurs in under one hour, that test condition cannot be used.
- 408 k) Cytotoxicity past the 10⁻¹ dilution is unacceptable for testing. Alternative neutralizers or
409 column filtration (e.g., Sephadex) may be used to mitigate cytotoxicity. See ASTM
410 Method E1482-12. Standard Practice for Use of Gel Filtration Columns for Cytotoxicity
411 Reduction and Neutralization (Reapproved 2017) for further information on column
412 filtration.
- 413 **3) 3-Part Soil Effect on Cell Line.**
- 414 a) Make the 3-part soil (see section 14e but withhold the virus).
- 415 b) Add 10 µL of the soil to 20 mL of CGM, equilibrated to 37±1°C.
- 416 c) Remove the CGM from the cells and add 1 mL of this solution to 4 wells on a 24 well
417 plate with an 80-95% confluent monolayer of cells. Have at least one well as a negative
418 control (e.g., CGM alone).
- 419 d) Incubate plate as appropriate and observe daily for cytotoxicity. No cytotoxicity should
420 be observed.

421

Figure 2: Neutralization Schematic

Treatment 1

Add 50 μL of test substance to each vessel. At timed intervals add 10 mL neutralizer and swirl by hand.




Add 10 μL of *Test Suspension B* to each vessel containing 50 μL test substance and 10 mL neutralizer.



Vortex and hold for 10 min at $21\pm 3^\circ\text{C}$. Proceed to vortexing/plating.

Treatment 2


Add 10 μL of *Test Suspension B* to each vessel containing 10 mL neutralizer.



Vortex and hold for 10 min at $21\pm 3^\circ\text{C}$. Proceed to vortexing/plating.

Treatment 3

Add 10 μL of *Test Suspension B* to each vessel containing 10 mL PBS.



Vortex and hold for 10 min at $21\pm 3^\circ\text{C}$. Proceed to vortexing/plating.


Treatment 4

Add 1 sterile carrier to each vessel. At timed intervals, add 10 mL neutralizer and swirl by hand.



Wait 10 s

Add 10 μL of *Test Suspension B* to each vessel containing the carrier and 10 mL neutralizer.



Vortex and hold for 10 min at $21\pm 3^\circ\text{C}$. Proceed to vortexing/plating